Saturday, March 26, 2011

NIH's State of the Knowledge conference on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, April 7-8


NIH's State of the Knowledge conference on Myalgic Encephalomyelitis:
Workshop Overview

Chronic fatigue syndrome (CFS), also referred to as myalgic encephalomyelitis (ME), is a poorly-defined, debilitating disease that affects roughly 17 million people worldwide (1 to 4 million in the United States) and it is diagnosed 2 to 4 times more often in women. Research on ME/CFS has been hampered by the lack of a universally accepted case definition, etiological agent, diagnostic criteria, or treatment.

The workshop will bring together subject matter experts who will discuss multiple aspects of ME/CFS, including epidemiology, etiology, pathophysiology, diagnosis and treatment. The workshop panelists will identify gaps in knowledge and opportunities for advancing biomedical research.

Investigators interested in pursuing research on ME/CFS are particularly encouraged to attend. This workshop is open to the public and will be webcast.

Sponsored by
The Office of Research on Women's Health,
National Institutes of Health (NIH)
In collaboration with
The Trans-NIH ME/CFS Research Working Group
If you have any questions, call (703) 925-9455 ext. 0 or e-mail icg@infinityconferences.com

Preliminary Agenda



Day 1 – Thursday, April 7

8:00 – 8:05
Welcoming

8:05 – 8:15
Opening

8:15 – 9:15
Plenary talks

9:15 – 10:45
Infectious diseases

10:45 – 11:00
Morning break

11:00 – 12:15
Systems biology

12:15 – 1:00
Lunch (on your own)

1:00 – 2:00
Immunology

2:00 – 3:15
Neurology

3:15 – 3:30
Afternoon break

3:30 – 5:00
Exercise physiology and energy metabolism



Day 2 – Friday, April 8

8:00 – 8:15
Reconvene

8:15 – 10:20
Diagnosis and biomarkers

10:20 – 10:35
Morning break

10:35 – 12:30
Treatment

12:30 – 1:30
Lunch (on your own)

1:30 – 2:30
Communication outreach

2:30 – 2:45
Afternoon break

2:45 – 4:45
Summary and conclusions

4:45 – 5:00
Closing
Thanks to Frank Twisk: hetalternatief.org

No comments:

Post a Comment